NCT05770531View on ClinicalTrials.gov

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

August 1, 2028

Study Completion Date

October 1, 2028

Conditions
Metastatic HER2-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection for banking

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biospecimen Collection

Undergo blood sample collection for ctDNA evaluation

BIOLOGICAL

Sacituzumab Govitecan

Given by IV

Trial Locations (1)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER